How Much Does It Cost to Private Label Supplements?

what may a supplement legally claim here?

A private-label supplement may claim it supports how the body normally functions, never that it treats, cures, or prevents a disease. That split comes from 21 CFR 101.93(g), where FDA lists ten separate ways ordinary marketing copy crosses from a lawful structure/function claim into an illegal disease claim. Two of the ten catch most advertiser copy on sight: describing a disease's characteristic symptoms without naming the disease, and naming the disease inside the product itself. FDA's own compliance guide is blunt about the second one, stating that "names such as 'CarpalHealth' or 'CircuCure' are disease claims because they are implied disease claims for carpal tunnel syndrome and circulatory disorders, respectively."

The 101.93(c) disclaimer you're required to print on the label doesn't fix a claim that's already crossed that line. If your copy names a disease or describes its symptoms, the standard not-evaluated-by-FDA disclaimer changes nothing about the underlying violation. You still owe FDA's Office of Dietary Supplement Programs a 30-day notification once you start marketing a structure/function statement, disclaimer or not.

The disclaimer is a condition of the safe harbor, not a repair kit for what's already outside it.

who is the buyer, really?

The buyer asking this question is almost always a direct-response operator, not a retail brand with a shelf-space budget. You're running paid traffic to a VSL or an advertorial, and you need inventory in hand before you know whether the offer converts at scale. That changes the math: minimum order quantity and lead time usually matter more to you than the lowest possible per-unit cost.

Two buyer profiles show up in the manufacturer data. One tests cheap: platforms like Supliful advertise a zero-unit minimum on dropship white-label formulas, so you can list a product and fulfill orders one at a time while you validate the angle. The other commits early: SMP Nutra's stock formulas start at $4 to $20 per unit, but only at a 2,500-to-5,000-bottle-per-SKU commitment, which locks up real capital before a single ad has run. Neither is wrong; the choice depends on how confident you already are in the offer.

Confidence is the variable, not taste.

what does the enforcement record show?

The enforcement record shows the FTC treats a false supplement claim as expensive, not merely embarrassing. FTC v. Tarr Inc., settled in 2017 over fake celebrity endorsements and undisclosed rebill traps, carried a $179 million judgment suspended down to about $6.4 million actually collected. FTC v. Health Formulas, settled in 2016 over weight-loss supplements sold through negative-option billing, carried a $105 million judgment suspended to roughly $9.2 million in surrendered assets.

The joint-pain niche has its own case on record, and it maps almost exactly onto copy that still runs today. In FTC v. A.S. Research, doing business as Synovia, the FTC alleged the marketers claimed their supplement would "pave the 'pot holes' in damaged joints, replace expensive injected medications, and reduce arthritis pain by 95 percent," and that they used fake testimonials and fake doctor endorsements to sell it. Announced in December 2019, the case settled for $821,000, and the FTC returned almost $775,000 to purchasers the following year. Bureau of Consumer Protection director Andrew Smith summarized the underlying problem plainly: "this company claimed to sell a miracle supplement that cured joint pain and arthritis, but they lied to consumers about the product's results."

Andrew Smith's line still describes the pattern advertisers repeat every quarter.

More recent enforcement leans on a warning shot before the lawsuit. On April 13, 2023 the FTC sent Notices of Penalty Offenses to roughly 670 companies selling supplements and OTC drugs, warning per the FTC's own press release that a knowing violation now carries civil penalties up to $53,088 per instance. Receiving that notice is what turns your next unsubstantiated claim into a penalty case instead of a consent order.

what does the product actually cost to make?

A stock formula costs $4 to $20 per unit and a custom formula $5 to $30, per SMP Nutra's published FAQ, at a standard minimum of 2,500 to 5,000 bottles per SKU. That price already includes bottling, testing, seals, and labels. It does not include shipping, and it assumes a common, in-stock ingredient set rather than something exotic.

Per-bottle cost also swings hard by format. At roughly 5,000-unit production runs, one cost guide widely cited by formulators puts capsules and tablets at the cheap end and liquids at the expensive one, reported as industry-typical figures rather than a single manufacturer's rate card.

Volume changes the number more than format does. A standard 60-count capsule SKU is commonly quoted at $3.50 to $4.50 a bottle for a 1,500-unit first order, $2.50 to $3.50 at 5,000 units, $2.00 to $3.00 at 10,000 units, and $1.50 to $2.50 at 25,000 units. Treat those as directional: we could confirm the pattern across sources but not against a single manufacturer's exact rate card, though the direction holds everywhere it appears, and per-unit cost roughly halves between a first run and a 25,000-bottle run.

Custom formulation adds one-time costs on top of the per-unit price, and they add up fast: $2,000 to $15,000 for formulation development, $3,000 to $8,000 for stability testing, $5,000 to $20,000 for tooling such as softgel molds or tablet dies, $500 to $2,000 for label design and print plates, and $500 to $2,000 per batch for certificate-of-analysis testing. Stacked together, that's 20% to 40% on top of your quoted per-unit price, committed before you know the offer works. Whether you own that formula afterward depends on the contract language, not which term the manufacturer uses to describe the deal; the white label vs private label vs contract manufacturing distinction is worth reading before you sign anything.

what does the competition already run?

Competitors run minimum orders anywhere from zero to 5,000 units, and that spread is the real competitive lever, not the per-unit price. Supliful advertises a zero-unit minimum on dropship white-label formulas, so you can list a product and fulfill one order at a time. Makers Nutrition starts private-label stock formulas at 500 units. SMP Nutra requires 2,500 to 5,000 bottles per SKU and a hard 1,000-bottle equipment floor that can't be split across products.

Paying for that flexibility costs you: on-demand fulfillment runs roughly 1.8 to 2.5 times the per-unit price of buying at full manufacturing minimum order, since you're paying for someone else's warehouse space and small-batch runs instead of your own bulk commitment. If your market can't absorb a 2,500-unit order yet, the private label supplements with no minimum order in the UK page walks through what that trade-off looks like for a UK-facing brand specifically.

Geography changes the calculation again. A brand building for a market like South Africa carries its own import, currency, and logistics variables that a US minimum-order table doesn't capture, which the private label supplements South Africa page addresses directly. We could not verify Meta's live Ad Standards wording on personal-health claims this session; its policy pages returned an error instead of text, so read them directly before you write ad copy for any of these formats.

where does the claim ceiling bite hardest?

The claim ceiling bites hardest where the plain-English word for a symptom doubles as the name of a disease, and joint pain and arthritis is the clearest case. FDA's own preamble draws the line directly: describing a product as supporting cartilage and joint function is a lawful structure/function claim, while promising to reduce joint pain is not, because joint pain is itself a documented symptom of arthritis.

Varicose veins sit in a stranger spot. FDA's list of permitted aging-skin claims includes spider veins by name, but varicose veins appear on neither the permitted list nor the disease list, so every claim in that niche gets decided by context rather than a bright line. We counted the FDA warning letters naming "varicose veins" in the agency's own database: five, issued between April 2021 and November 2022, and none since, a documented history of letters with no matching history of FTC monetary judgments behind it.

A lawful FDA claim still has to clear a separate FTC bar, and the two aren't the same test. FTC's Health Products Compliance Guidance states plainly that "substantiation of health-related benefits will need to be in the form of randomized, controlled human clinical testing," so a perfectly legal structure/function claim can still be deceptive advertising without a clinical trial behind it.

what makes this niche harder than it looks?

What makes this harder than the per-unit price sheet suggests is everything that happens after the quote: tariffs, customs, testing, and the real meaning of an FDA-registered facility. FDA requires supplement facilities to register under 21 CFR 1.225, but registration is a database entry, not an independent approval of the facility or an inspection sign-off on your specific product. DSHEA gives FDA no authority to approve a dietary supplement before it reaches the market, and the agency does not test products before they're sold.

Landed cost moved under your feet in 2026. The Tax Foundation's tariff tracker puts the average effective US tariff rate at 6.6% for the year, the highest since 1969, after the Supreme Court struck down the earlier reciprocal tariffs in February and Section 301 tariffs of 10% to 12.5% took their place in July, with China-origin goods facing roughly 20%. If your ingredients or packaging come from overseas, that's a cost line your last quote almost certainly didn't include.

Lead time is the other line item people underprice. Stock formulas ship in 2 to 4 weeks, private label in 4 to 8, and a full custom formulation in 8 to 16, and identity testing alone, required on every incoming ingredient lot under cGMP, adds a minimum of 5 to 10 days on top. If you're building for the EU rather than the US, the private label supplement EU page covers where that timeline and the compliance list diverge further.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For educational pages, the supporting references should help readers verify search, crawlability, and public ad research context, especially Google helpful content guidance, Google SEO link best practices, and Meta Ad Library. Daily Intel then adds the direct-response interpretation layer so the page explains what the signal means for actual affiliate research decisions.

For deeper evaluation, continue through Nutra niche intelligence directory, Weight Loss Promotion Ideas: What the Evidence Shows, Weight Loss with Gluten Free: Free Until Exactly Where, Best Weight Loss Injection Deals: A Reference for Operators, Weight Loss Pills Over the Counter: The Practical Version, and What is a VSL?. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.